Compare Viatris Inc (VTRS) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs WD 40 Company — how do they compare? Viatris Inc trades at $17.58 (market cap $19.79B), while WD 40 Company trades at $237.72 (market cap $3.22B). The key difference: Viatris Inc is far larger — about 6.1× WD 40 Company's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| VTRS | WDFC | |
|---|---|---|
Market Cap | $19.79B | $3.22B |
Sector | Health | Technology |
52-Week High | $17.39 | $264.91 |
52-Week Low | $8.74 | $187.52 |
Enterprise Value | $32.00B | $3.27B |
Dividend Yield | 2.83% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
WDFC trades at $239.59, down 2.92% today, with a bullish technical signal supported by moving averages and ADX indicators. Recent Q2 2026 earnings beat expectations at $2.33 EPS versus $1.58 expected, driven by strong sales growth. The company maintains solid profitability with a 13.22% net income margin and positive operating cash flow of $87.93 million in 2025, though 2026 projections show slight margin compression.
The outlook is mixed: strong brand moat and consistent cash flow support dividends, but high valuation multiples (P/E 37.5) and analyst caution (71% hold rating) limit near-term upside. Risks include input cost pressures and competitive maintenance markets. Institutional sentiment leans neutral despite recent earnings strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
